Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Assess Efficacy and Safety of Neu2000KWL in Patients With Acute Ischemic Stroke Receiving Endovascular Therapy

Next Previous
X
Search
Trial Profile

A Phase II, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Assess Efficacy and Safety of Neu2000KWL in Patients With Acute Ischemic Stroke Receiving Endovascular Therapy

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nelonemdaz (Primary)
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms ENIS I; SONIC
  • Sponsors GNT Pharma

    • Most Recent Events

    • 06 Sep 2022 Results (n=209) assessing the safety and efficacy of nelonemdaz in patients with acute ischemic stroke receiving endovascular reperfusion therapy, published in the Stroke.
    • 14 Oct 2020 Top-line results are presented in a GNT Pharma media release.
    • 11 Jul 2017 Planned End Date changed from 1 Jul 2017 to 30 Dec 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top